EVOTEC SEINH O.N. overview

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk 11.12.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this announcement. Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding,...

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024 Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces change in Management Board 29.11.2024 / 07:31 CET/CEST The issuer is solely responsible for the content of this announcement. Dr Craig Johnstone steps down as Chief Operating Officer effective 31 December 2024 Distribution of responsibilities internally Hamburg, Germany, 29 November 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr...

HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for EUR11.00 per share in cash. The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the...

EQS-Ad-hoc: Evotec SE / Key word(s): Miscellaneous Comment on withdrawn non-binding offer 22-Nov-2024 / 16:55 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc: Comment on withdrawn non-binding offer Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9,...

HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share....